Wockhardt :td
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Wockhardt's recent strategic initiatives, particularly the global launch of its novel antibiotic Zaynich, are expected to significantly enhance revenue growth and profitability over the next 12-24 months. Management's confidence in a 'hockey stick' growth trajectory, supported by a robust pipeline of biosimilars and innovative products, positions the company favorably in a competitive landscape. The anticipated breakeven from Zaynich within 12-18 months, despite initial costs, underscores a commitment to long-term value creation. Additionally, the favorable currency depreciation is likely to bolster revenues from exports, aligning with Vista's forecast of stable revenue growth and improving margins. However, challenges such as rising input costs and geopolitical tensions could impact profitability. Overall, Wockhardt's focus on operational excellence and strategic product launches is expected to drive significant upside, with a target price reflecting a 75% expected upside. Key opportunities include the expansion of the biosimilar diabetes franchise and the successful commercialization of Zaynich, while headwinds may arise from pricing pressures in the US market and potential supply chain disruptions
Why We Like This Stock
- The global launch of Zaynich is expected to drive significant revenue growth and profitability
- Expansion of the biosimilar diabetes franchise is set to enhance market share and margins
- Favorable currency depreciation will likely boost revenues for export-oriented operations
Things To Watch Out For
- Rising input costs may exert pressure on margins across the sector
- Geopolitical tensions could disrupt supply chains and impact operational efficiency
- Pricing challenges in the US market may affect overall profitability
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 2,798 | 3,012 | 3,373 | 3,655 | 4,089 |
| Profit Before Tax (Cr.) | -354 | -16 | 323 | 462 | 486 |
| PBT Margin | -12.7% | -0.5% | 9.6% | 12.6% | 11.9% |
| Net Profit (Cr.) | -378 | -23 | 291 | 429 | 429 |
| Earnings Per Share | -22.8 | -0.8 | 18.8 | 25.2 | 26.5 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine, as well as offers insulin aspart regular and biphasic drug products. Further, the company offers delivery devices for insulin, including DispoPen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.